Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
Frontiers in Physiology · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of mechanisms linking gut dysbiosis to obesity-associated inflammation and examining three therapeutic intervention classes. It presents a conceptual model of how microbial changes perpetuate inflammation but does not report original findings, effect sizes, or comparative efficacy data to support clinical decision-making.
Journal article. Obese individuals; review covers both clinical and preclinical studies..
Obesity-associated dysbiosis perpetuates chronic inflammation through increased lipopolysaccharide translocation, reduced butyrate production, and compromised intestinal barrier integrity. Successful microbial restructuring requires not only compositional shifts but also functional restoration of microbial metabolite production, particularly short-chain fatty acids. Three major intervention approaches evaluated: fecal microbiota transplantation, probiotic and prebiotic supplementation, and next-generation targeted microbial therapies.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides a conceptual framework for understanding how gut dysbiosis contributes to obesity-related metabolic disease, but offers no quantified efficacy data or clinical trial results to guide therapeutic choices. Practitioners should consult primary evidence for specific intervention outcomes.
This is a narrative review synthesizing mechanistic evidence and existing studies without new primary data, raising and exploring questions about dysbiosis-inflammation pathways rather than answering them with original results.
This review provides a conceptual framework for understanding how gut dysbiosis contributes to obesity-related metabolic disease, but offers no quantified efficacy data or clinical trial results to guide therapeutic choices. Practitioners should consult primary evidence for specific intervention outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is characterized by a chronic low-grade inflammatory state that contributes to insulin resistance, type 2 diabetes, and metabolic syndrome. The gut microbiota has emerged as a critical mediator of this inflammatory process through multiple interconnected mechanisms including metabolic endotoxemia, short-chain fatty acid dysregulation, and intestinal barrier dysfunction. This review synthesizes current evidence on the structural and functional alterations of the gut microbiome in obesity, examines the mechanistic pathways linking dysbiosis to systemic inflammation, and critically evaluates therapeutic strategies aimed at restructuring the obese gut microbial community. We focus on three major intervention approaches: fecal microbiota transplantation, probiotic and prebiotic supplementation, and next-generation targeted microbial therapies. Analysis of clinical and preclinical studies reveals that successful microbial restructuring requires not only compositional shifts but also functional restoration of microbial metabolite production, particularly short-chain fatty acids. The evidence supports a model wherein obesity-associated dysbiosis perpetuates chronic inflammation through increased lipopolysaccharide translocation, reduced butyrate production, and compromised intestinal barrier integrity. Restoring microbial eubiosis through targeted interventions offers a promising avenue for resolving chronic low-grade inflammation and improving metabolic health outcomes in obese individuals.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.